Dianthus Therapeutics, Inc.
NASDAQDianthus Therapeutics has cleared its earnings event with momentum intact — and the data since the print shows shorts retreating while institutional conviction holds firm. The most notable post-earnings shift is in short positioning. Short interest has edged down to 20.9% of the free float, trimming roughly 1.3% over the week after the sharp build that preceded the report. The…
Snapshot as of 6 Aug 2026
Dianthus Therapeutics has cleared its earnings event with momentum intact — and the data since the print shows shorts retreating while institutional conviction holds firm. The most notable post-earnings shift is in…
Dianthus Therapeutics heads into tonight's earnings report with options traders at their most bullish in recent memory — while a large short base keeps the setup charged on both sides. The options signal is the…
Dianthus Therapeutics enters the week with a genuinely split picture: short interest is running at 15.6% of the free float — a meaningfully elevated position — yet the lending market is telling a completely different…
Dianthus Therapeutics reports today after market close with short sellers in retreat and analysts broadly constructive — but insider selling from the CFO adds a note of caution to an otherwise positive setup. The most…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for DNTH — free to start on ORTEX.
Sign up for free →Open DNTH on ORTEX